Invention Grant
- Patent Title: Dosage regimen for pegylated interferon
-
Application No.: US15518423Application Date: 2015-11-06
-
Publication No.: US11559567B2Publication Date: 2023-01-24
- Inventor: Christoph Klade , Oleh Zagrijtschuk , Ko-Chung Lin
- Applicant: PharmaEssentia Corporation
- Applicant Address: TW Taipei
- Assignee: PharmaEssentia Corporation
- Current Assignee: PharmaEssentia Corporation
- Current Assignee Address: TW Taipei
- Agency: Cesari & McKenna, LLP
- Priority: EP14192114 20141106
- International Application: PCT/US2015/059410 WO 20151106
- International Announcement: WO2016/073825 WO 20160512
- Main IPC: A61K38/21
- IPC: A61K38/21 ; A61K47/60 ; C07K14/56 ; C07K14/555
Abstract:
A pegylated type I interferon for use in treating an infectious disease, cancer, or myeloproliferative disease in a subject in need thereof, wherein a 50 to 540 μg dose of the pegylated type I interferon is administered to the subject at a regular interval for a treatment period, the interval being 3 to 8 weeks.
Public/Granted literature
- US20170326206A1 DOSAGE REGIMEN FOR PEGYLATED INTERFERON Public/Granted day:2017-11-16
Information query
IPC分类:
